Elevation of the tumor marker CA19‐9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report

Abstract

Key Clinical MessageSerum carbohydrate antigen 19‐9 (CA19‐9) is used for recurrence surveillance in patients with resected pancreatic ductal adenocarcinoma (PDAC). This report describes the association of increasing CA19‐9 in a male PDAC survivor with presence of prostatic hyperplasia. Unexplained elevation of CA19‐9 in male PDAC survivors might be attributable to benign prostatic conditions.